Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
NCT ID: NCT05681949
Last Updated: 2023-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1200 participants
INTERVENTIONAL
2023-11-30
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Can ADBoard achieve a high level of similar recommendations as physicians' tumor conferences? Can ADBoard consider a more complete set of patient-related data than in physicians' tumor conferences? Can ADBoard reduce the time between the first time the patient is discussed at the tumor conference and the start of the recommended treatment plan? Participants will have their hepatobiliary tumor treatments determined by either tumor conference with ADBoard, or tumor conference without ADBoard.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
NCT06849180
Artificial Intelligence and Hepatocellular Carcinoma
NCT05637788
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
NCT02798510
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
NCT01291615
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
NCT05184400
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants' cases discussed in tumor conference without ADBoard
Participants' cases are discussed in tumor conference without the use of ADBoard, according to conventional practice.
No interventions assigned to this group
Participants' cases discussed in tumor conference with ADBoard
Participants' cases will be evaluated by ADBoard directly before they are discussed in the tumor conference.
ADBoard
Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADBoard
Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Valid informed consent
* Patient information available in the hospital information system or Health Data Platform (HDP)
* Enrollment in the hepatobiliary tumor conference
* Diagnosis of any of the following entities: Colorectal liver metastasis, Gallbladder carcinoma, Hepatocellular carcinoma (HCC), mixed cell carcinoma, or fibrolamellar carcinoma, Perihilar cholangiocarcinoma (Klatskin tumors), Intrahepatic cholangiocarcinoma (iCC)
Exclusion Criteria
* Missing findings in the hospital information system
* Patient is seeking for a second opinion and is not being treated at the study institution
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Research Center for Artificial Intelligence
UNKNOWN
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Felix Krenzien
Senior Physician and Advanced Clinician Scientist, Charité - Universitätsmedizin Berlin
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Felix Krenzien
Role: PRINCIPAL_INVESTIGATOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Surgical Clinic, Campus Virchow-Klinikum / Campus Charité Mitte, Charité - Universitätsmedizin Berlin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ng SST, Oehring R, Ramasetti N, Roller R, Thomas P, Chen Y, Moosburner S, Winter A, Maurer MM, Auer TA, Kamali C, Pratschke J, Benzing C, Krenzien F. Concordance of a decision algorithm and multidisciplinary team meetings for patients with liver cancer-a study protocol for a randomized controlled trial. Trials. 2023 Sep 9;24(1):577. doi: 10.1186/s13063-023-07610-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EA4/169/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.